On Invalid Date, Aeterna Zentaris (NASDAQ: AEZS) reported Q1 2023 earnings per share (EPS) of -$0.88, up 62.96% year over year. Total Aeterna Zentaris earnings for the quarter were -$4.26 million. In the same quarter last year, Aeterna Zentaris's earnings per share (EPS) was -$0.54.
On Invalid Date, Aeterna Zentaris (NASDAQ: AEZS) reported Q1 2023 revenue of $2.13 million up 40.28% year over year. In the same quarter last year, Aeterna Zentaris's revenue was $1.52 million.
What was AEZS's revenue growth in the past year?
As of Q2 2023, Aeterna Zentaris's revenue has grown 22.35% year over year. This is 47.42 percentage points lower than the US Biotechnology industry revenue growth rate of 69.78%. Aeterna Zentaris's revenue in the past year totalled $6.25 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.